Provided by Tiger Trade Technology Pte. Ltd.

OKYO Pharma Limited

1.60
-0.1000-5.88%
Volume:234.90K
Turnover:376.09K
Market Cap:82.19M
PE:-14.36
High:1.72
Open:1.68
Low:1.52
Close:1.70
52wk High:3.35
52wk Low:1.03
Shares:51.37M
Float Shares:31.35M
Volume Ratio:2.36
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1114
EPS(LYR):-0.1192
ROE:-2968.51%
ROA:-104.63%
PB:-24.07
PE(LYR):-13.42

Loading ...

OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026

TIPRANKS
·
23 hours ago

OKYO Pharma Abstract Earns Presentation Slot at ARVO 2026 Annual Meeting

Reuters
·
23 hours ago

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

GlobeNewswire
·
23 hours ago

Piper Sandler Initiates Coverage on OKYO Pharma With Overweight Rating, $7 Price Target

MT Newswires Live
·
Feb 20

OKYO Pharma Initiated at Overweight by Piper Sandler

Dow Jones
·
Feb 20

Okyo Pharma initiated with an Overweight at Piper Sandler

TIPRANKS
·
Feb 20

OKYO Pharma Announces Public Offering of Ordinary Shares

GlobeNewswire
·
Feb 13

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

GlobeNewswire
·
Feb 11

OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners

TIPRANKS
·
Feb 11

OKYO Pharma ernennt Flavio Mantelli zum Chief Medical Officer

Reuters
·
Feb 10

OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial

TIPRANKS
·
Jan 31

OKYO Pharma reports half-year cash on hand of USD 4.2 million, up 163%

Reuters
·
Jan 31

OKYO Pharma to Present Phase 2 Urcosimod Efficacy Data at 2026 ASCRS Annual Meeting

Reuters
·
Jan 31

OKYO Pharma Announces Successful Type C Meeting with the FDA

GlobeNewswire
·
Jan 28

FDA Authorizes Compassionate Use of Urcosimod for Neuropathic Corneal Pain

Reuters
·
Jan 26

Analysts’ Top Healthcare Picks: OKYO Pharma Limited Sponsored ADR (OKYO), vTv Therapeutics (VTVT)

TIPRANKS
·
Jan 24

FDA Approves Compassionate Use Of Urcosimod (0.05%) For The Treatment Of Neuropathic Corneal Pain

Reuters
·
Jan 23

OKYO Pharma Names Robert J. Dempsey as CEO

Reuters
·
Jan 05

OKYO Pharma to Ring the Opening Bell at Nasdaq

GlobeNewswire
·
Dec 19, 2025

OKYO Pharma Chairman Gabriele Cerrone Increases Stake with Additional Share Purchase

Reuters
·
Dec 15, 2025